Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

BACKGROUND: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS: Observational clinical study was perfo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Ophthalmol
Asıl Yazarlar: Waizel, Maria, Todorova, Margarita G., Masyk, Michael, Wolf, Katharina, Rickmann, Annekatrin, Helaiwa, Khaled, Blanke, Björn R., Szurman, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5442868/
https://ncbi.nlm.nih.gov/pubmed/28535756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-017-0471-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller